ClinicalTrials.gg
CompletedNCT04042103Updated Jun 19, 2025Results posted

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

A Phase 2 interventional study of Tapinarof cream, 1% in Plaque Psoriasis, sponsored by Organon and Co. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-06-19.

Sponsored by Organon and Co · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies testing tapinarof in Psoriasis — 3 open to participants now, 3 under way, 1 of them phase 3. tapinarof · Psoriasis.

Enrollment
16th of 19
21 · median 58
Started
2019
with 3 others
Phase 2
3 of 19
none open now
Registered
9th of 19
by date
Lead sponsor
7 of 19
Organon and Co

Among the 19 studies testing tapinarof in Psoriasis, this one is the 16th largest by enrollment, is one of 4 that started in 2019, is one of 3 in phase 2, and was the 9th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 19 studies testing tapinarof in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About tapinarof

tapinarof: first FDA approval 2022 (VTAMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing tapinarof in Psoriasis, or all of them as a file.
02

Study summary

This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects age 18 to 75 with a confirmed clinical diagnosis of plaque psoriasis and stable disease for at least 6 months prior to the study
  • BSA involvement ≥ 20%
  • PGA score of ≥ 3 at screening
  • Females of child bearing potential and male subjects who are engaging in sexual activity that could lead to pregnancy agree to follow the specified guidance throughout the study
  • Capable of giving written

Exclusion criteria

Exclusion Criteria:

  • Psoriasis other than plaque variant
  • Any sign of infection of any of the psoriatic lesions
  • Evidence of significant hepatic, renal, respiratory, endocrine, hematologic, neurologic, psychiatric, or cardiovascular (CV) system abnormalities or laboratory abnormality that will affect the health of the subject or interfere with the interpretation of the results
  • Ultraviolet (UV) light therapy or prolonged exposure to natural or artificial sources of UV radiation within 4 weeks prior to the Baseline visit and/or plans to have such exposures during the study which could potentially impact the subject's psoriasis
  • Use of any prohibited medication within the indicated period before the first dose of study drug
  • Pregnant females or lactating females
  • The subject has received an product within 30 days, 5 half-lives, or twice the duration of the biological effect of the study drug (whichever is longer) prior to first dose of study drug
  • Current or a history of cancer within 5 years except for fully excised skin basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
  • Previous known participation in a clinical study with tapinarof
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Tapinarof (DMVT-505) cream, 1%

    Tapinarof (DMVT-505) cream, 1% applied topically once daily

    Drug: Tapinarof cream, 1%

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)

    Frequency and severity of AEs (local and systemic)

    Time frame: Baseline to Week 4

  2. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs

    Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance.

    Time frame: Baseline to Week 4 or Follow-Up (7-10 days after Week 4 Visit)

  3. Number of Participants With Irritation as Assessed by the Local Tolerability Scale

    At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study.

    Time frame: Day 1, Day 15, Day 29

  4. Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau

    The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.

    Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)

  5. Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax

    The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.

    Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)

  6. Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2

    The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.

    Time frame: Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)

Secondary outcomes

  1. Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29)

    Identify clinically relevant effect of tapinarof on cardiac conduction

    Time frame: Baseline and Day 1

  2. Analysis of the Relationship Between Plasma Concentration and ΔQTcF

    The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated.

    Time frame: Day 1

  3. Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)

    The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome.

    Time frame: Baseline to Day 29

  4. Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)

    The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.

    Time frame: Baseline to Day 29

  5. Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected

    The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

    Time frame: Baseline to Day 29

07

Results

Posted May 6, 2022

Participant flow

Participant flow — Overall Study
MilestoneTapinarof (DMVT-505) Cream, 1%
Started21
Completed19
Not completed2
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryNumber of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)

Frequency and severity of AEs (local and systemic)

Time frame:
Baseline to Week 4
Reported as:
Count of participants · Participants
Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs)
ParticipantsTapinarof (DMVT-505) Cream, 1%
Experienced an AE12
Experienced a Treatment-Related AE6
Experienced a Grade 3 (severe) AE2
Experienced a Grade 4 (life-threatening) AE0
Experienced a Grade 5 (fatal) AE0
Experienced an SAE1
Experienced a Treatment-related SAE0
Experienced TEAE leading to discontinuation from study/drug0
PrimaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs

Changes in laboratory values, biomarker values, ECG results and vital signs were assessed for clinical relevance.

Time frame:
Baseline to Week 4 or Follow-Up (7-10 days after Week 4 Visit)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Values, Biomarker Values, ECG Results or Vital Signs
ParticipantsTapinarof (DMVT-505) Cream, 1%
Clinically Meaningful changes in hematology.0
Clinically meaningful changes in chemistry0
Clinically meaningful changes in urinalysis0
Clinically meaningful changes in tryptase0
Clinically meaningful changes in ECG parameters0
Clinically meaningful changes in vital signs0
PrimaryNumber of Participants With Irritation as Assessed by the Local Tolerability Scale

At each specified study visit, the Investigator (or qualified evaluator) assessed the presence and overall degree of irritation at the application sites, according to the LTS. The score will ideally represent an 'average' across all application sites. To the fullest extent possible, the same Investigator (or designated evaluator) will perform all tolerability assessments for an individual participant throughout the study.

Time frame:
Day 1, Day 15, Day 29
Reported as:
Count of participants · Participants
Number of Participants With Irritation as Assessed by the Local Tolerability Scale
ParticipantsTapinarof (DMVT-505) Cream, 1%
Baseline — No Irritation14
Baseline — Mild5
Baseline — Moderate1
Baseline — Severe1
Baseline — Very Severe0
Day 15 — No Irritation14
Day 15 — Mild5
Day 15 — Moderate1
Day 15 — Severe0
Day 15 — Very Severe0
Day 29 — No Irritation17
Day 29 — Mild2
Day 29 — Moderate0
Day 29 — Severe0
Day 29 — Very Severe0
PrimaryTapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau

The AUC in plasma is a pharmacokinetic parameter that describes the overall exposure of the drug.

Time frame:
Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Reported as:
Mean · pg*h/ml
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: AUCo-tau
pg*h/mlTapinarof (DMVT-505) Cream, 1%
Day 1: tapinarof8037.29 ± 6204.935
Day 29: tapinarof1985.54 ± NA
PrimaryTapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax

The Cmax is a pharmacokinetic parameter that describes the highest concentration of the drug that is achieved after dosing.

Time frame:
Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Reported as:
Mean · pg/mL
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Cmax
pg/mLTapinarof (DMVT-505) Cream, 1%
Day 1: tapinarof Cmax898.33 ± 1448.084
Day 29: tapinarof Cmax116.09 ± 148.424
PrimaryTapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2

The tmax is a pharmacokinetic parameter that describes the time point at which the highest concentration of the drug is achieved after dosing.

Time frame:
Day 1 and Day 29 (PK samples collected at pre-dose and at 1, 2, 3, 4, 5, 8, 12, and 24 hours after dosing)
Reported as:
Mean · hours
Tapinarof and Tapinarof Sulfate (Metabolite) Plasma PK Parameters on Day 1 and Day 29: Tmax and t1/2
hoursTapinarof (DMVT-505) Cream, 1%
Day 1: tmax4.39 ± 5.476
Day 29: tmax4.02 ± 3.005
Day 1: t1/26.41 ± 0.691
SecondaryChange From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29)

Identify clinically relevant effect of tapinarof on cardiac conduction

Time frame:
Baseline and Day 1
Reported as:
Least squares mean · ms
Change From Baseline in QTcF (ΔQTcF) at Each Post-treatment Time Point on the Sampling Day With the Higher Cmax (Day 1 or Day 29)
msTapinarof (DMVT-505) Cream, 1%
Day 1 1 h Post-dose-7.2 ± 1.79
Day 1 2 h Post-dose-1.1 ± 2.92
Day 1 3 h Post-dose-4.3 ± 1.88
Day 1 4 h Post-dose-2.3 ± 3.04
Day 1 5 h Post-dose-4.9 ± 2.87
Day 1 8 h Post-dose-3.0 ± 2.60
Day 1 12 h Post-dose-1.6 ± 2.18
Day 1 24 h Post-dose-3.4 ± 1.97
SecondaryAnalysis of the Relationship Between Plasma Concentration and ΔQTcF

The relationship between tapinarof plasma concentrations and ∆QTcF was investigated using a linear mixed-effects modeling approach with ΔQTcF as the dependent variable. A linear model with an intercept was fitted for tapinarof plasma concentrations, which represented the data in an acceptable way. The slope of tapinarof plasma concentration in the concentration-QTc relationship was estimated.

Time frame:
Day 1
Reported as:
Number · ms per pg/ml
Analysis of the Relationship Between Plasma Concentration and ΔQTcF
ms per pg/mlTapinarof (DMVT-505) Cream, 1%
Analysis of the Relationship Between Plasma Concentration and ΔQTcF-0.00016 (-0.002172 to 0.001844)
SecondaryMean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)

The PGA is a clinical tool for assessing the current state/severity of a subject's psoriasis at a given timepoint. It is a static 5-point morphological assessment of overall disease severity, as determined by the investigator, using the clinical characteristics of erythema, scaling, and plaque thickness/elevation as guidelines. Higher PGA scores represent more severe disease. This scale ranges from 0 to 5, with 0 = best outcome.

Time frame:
Baseline to Day 29
Reported as:
Mean · score on a scale
Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)
score on a scaleTapinarof (DMVT-505) Cream, 1%
Mean Change From Baseline to Day 29 in Physician's Global Assessment (PGA)-1.2 ± 1.03
SecondaryMean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)

The Psoriasis Area and Severity Index (PASI) scoring system combines the assessment of lesion severity and extent of affected area into a single score: 0 (no disease) to 72 (maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, and legs). Each area is assessed for 3 signs: erythema (redness), induration (plaque thickness), and scale. The severity of each sign in each body area is assessed and scored independently using a 5-point scale, where 0=none, 1=slight, 2=mild, 3=moderate, 4=severe. Each area is also assessed for percent of skin involved: 0 = (0%), 1 = (1-\<10%), 2 = (10-\<30%), 3 = (30-\<50%), 4 = (50 -\<70%), 5 = (70-\<90%), 6 = (90-100%). The individual scores are multiplied by a weighted factor for each body region; the sum of these scores gives the overall PASI score. Higher scores indicate more severe disease. PASI is a static assessment made without reference to previous scores.

Time frame:
Baseline to Day 29
Reported as:
Mean · score on a scale
Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)
score on a scaleTapinarof (DMVT-505) Cream, 1%
Mean Change From Baseline to Day 29 Psoriasis Area and Severity Index (PASI)-15.14 (-19.61 to -10.66)
SecondaryMean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected

The assessment of %BSA affected is an estimate of the percentage of total involved skin with psoriasis. For the purpose of clinical estimation, the total palmar surface of the subject's palm and digits may be assumed to be approximately equivalent to 1% BSA. The %BSA affected by psoriasis will be evaluated (from 0% to 100%). %BSA is a static assessment made without reference to previous scores.

Time frame:
Baseline to Day 29
Reported as:
Mean · percentage of BSA affected
Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected
percentage of BSA affectedTapinarof (DMVT-505) Cream, 1%
Mean Change From Baseline to Day 29 in Percent of Total Body Surface Area (%BSA) Affected-14.44 (-19.84 to -9.04)

Adverse events

Collected over Study Period (29 days) + Follow-up period (7 to 10 days). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tapinarof (DMVT-505) Cream, 1%0/21 (0%)1/21 (4.8%)12/21 (57.1%)
Most frequent serious events
Most frequent serious events
EventTapinarof (DMVT-505) Cream, 1%
pancreatitisGastrointestinal disorders1/21
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTapinarof (DMVT-505) Cream, 1%
FolliculitisInfections and infestations4/21
HeadacheNervous system disorders4/21
Back painMusculoskeletal and connective tissue disorders2/21
PruritusSkin and subcutaneous tissue disorders2/21
Abdominal PainGastrointestinal disorders1/21
NauseaGastrointestinal disorders1/21
PancreatitisGastrointestinal disorders1/21
Chest PainGeneral disorders1/21
FatigueGeneral disorders1/21
PainGeneral disorders1/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tapinarof (DMVT-505) Cream, 1%
Mean51.8 ± 13.91
Sex: Female, Male
Sex: Female, Male(Participants)Tapinarof (DMVT-505) Cream, 1%
Female8
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tapinarof (DMVT-505) Cream, 1%
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White16
More than one race0
Unknown or Not Reported1
08

Study locations

6 sites
  • Dermavant Investigational Site
    Encino, California 91436, United States
  • Dermavant Investigational Site
    Sanford, Florida 32771, United States
  • Dermavant Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Dermavant Investigational Site
    Austin, Texas 78759, United States
  • Dermavant Investigational Site
    San Antonio, Texas 78213, United States
  • Dermavant Investigational Site
    Spokane, Washington 99202, United States
09

References and documents

Publications

  • Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, Tabolt G, Wilson T, Somerville MC, DellaMaestra W, Piscitelli SC. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics. Am J Clin Dermatol. 2022 Jan;23(1):83-91. doi: 10.1007/s40257-021-00641-4. Epub 2021 Oct 28. PubMed 34713415 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2019 to primary completion in Jan 2020, 5 months.

Results were first posted in May 2022, 2 years 3 months after primary completion.

Of 146 industry-sponsored phase 2 interventional studies under Psoriasis, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 20. This study's 5 months is below that.

Counting every sponsor, half of 175 studies reached it within 14 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2019
First posted
Aug 1, 2019
StartActual
Jul 23, 2019
Primary completionActual
Jan 9, 2020
CompletionActual
Jan 9, 2020
Results first posted
May 6, 2022
Last update
Jun 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04042103
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Aug 1, 2019
Start date
Jul 23, 2019
Primary completion
Jan 9, 2020
Completion
Jan 9, 2020
Results posted
May 6, 2022
Last update
Jun 19, 2025

Study contacts

Michael McLaughlin
study director · Dermavant Sciences, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tapinarof

Start the discussion